Key result
Aspirin reinitiation with a PPI prevents recurrent upper GI bleeding after aspirin-induced hemorrhage.
Why the study?
The management of cardiovascular event prophylaxis after aspirin-induced upper gastrointestinal bleeding lacks consensus and optimal strategies are uncertain.
Does reinitiating aspirin therapy with a proton pump inhibitor prevent recurrent GI bleeding in patients with a history of aspirin-induced GI bleeding requiring cardiovascular prophylaxis?
Case Report (n=1)
Does reinitiating aspirin therapy with a proton pump inhibitor prevent recurrent GI bleeding in patients with a history of aspirin-induced GI bleeding requiring cardiovascular prophylaxis?
The best approach to preventing recurrent aspirin-induced GI bleeds in patients requiring primary cardiovascular prophylaxis is to administer a proton pump inhibitor concomitantly with aspirin therapy.
May support PPI co-therapy on aspirin reinitiation after GI bleed; hypothesis-generating for cardiovascular prophylaxis patients.
OBJECTIVE: To describe a case of continued aspirin use for primary prevention of a cardiovascular event in a patient post-aspirin-induced upper gastrointestinal (GI) bleed and evaluate published evidence to determine whether reinitiating aspirin therapy for this patient was appropriate. CASE SUMMARY: A 65-year-old man had been taking chronic low-dose (81 mg/day) aspirin therapy since 2002 for primary prevention of a cardiovascular event. He developed an upper GI bleed with lowered hemoglobin (9 mg/dL) and hematocrit (26.3%) after concomitantly taking 2 doses of naproxen (220 mg each). An objective causality assessment with the Naranjo probability scale revealed a probable adverse reaction of an upper GI bleed associated with concomitant naproxen and aspirin use. No further naproxen was taken. Aspirin was discontinued and pantoprazole was started, with resolution of the bleeding. Aspirin was restarted 2.5 months after pantoprazole was initiated, and no further bleeding occurred. DISCUSSION: Upper GI bleeds associated with aspirin therapy are well described in the literature. The management of cardiovascular event prophylaxis after a GI bleed is often controversial; consensus in regard to the optimal method of management does not exist. We evaluated GI protection strategies for patients with a history of aspirin-induced GI bleeding requiring cardiovascular prophylaxis. We found that the benefit of aspirin for the primary prevention of cardiovascular events needs to be carefully balanced with the risks associated with its use. The current literature supports that the best approach to prevent recurrent aspirin-induced GI bleeding is to administer a proton pump inhibitor with aspirin therapy. CONCLUSIONS: The benefit of aspirin for primary prevention of cardiovascular events needs to be carefully balanced with the risks associated with its use. Based on the current literature, the best approach to preventing recurrent aspirin-induced GI bleeds is to administer a proton pump inhibitor concomitantly with aspirin therapy.
No takes yet. Share an insight, caveat, or question.
Adly et al. (2013) conducted a case report in Aspirin-induced upper gastrointestinal bleed (n=1). Aspirin and proton pump inhibitor (pantoprazole) was evaluated on Recurrent GI bleeding. Reinitiating aspirin therapy concomitantly with a proton pump inhibitor prevented recurrent gastrointestinal bleeding in a 65-year-old man with a prior aspirin-induced upper GI bleed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: